Replies to post #2289 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

More info than I thought in the abstract. My previous post where I stated

untreated patients are able to stay on treatment longer since they should be healthier

got me pondering. Here I am thinking, well, if the main benefit of giving posi to 1st-line patients is, for example, instead of only being able to give pozi, say, for 6 months to patients who may be on palliative care, you're giving it for a year or more to much healthier patients. But then I said oh oh, the abstract indicated PFS of only 5.6 months. Is that the average that includes healthier patients? If that is the case, you won't see that much of a benefit for 1st line. So I reread the abstract

the planned EGFR cohort of 50 patients was fully enrolled, and 40 patients were evaluated for response. 65.1% of patients had received at least two prior lines of therapy for metastatic disease.

it also states

Responses were observed in 8/13 (62%) patients that were previously treated with TKI. Median PFS was 5.6mo

So it appears to me they are excluding 1st-line patients from these stats. I'm pretty sure we're going to get stats on the 35% of patients who were 1st and second-line, in addition, to the 65% of patients who had at least 2 lines of therapy. So we'll get a pre-view of what pozi can do in treatment naive patients. So it's a 'Back to the Future' glimpse on the new 2 new treatment naive cohorts that started dosing this week come the 24th!